Tepkinly access in Egypt: the EDA named-patient pathway
How Egypt patients legally obtain Tepkinly (epcoritamab) when the locally registered indication, presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Quick orientation
Tepkinly (epcoritamab) is a CD3xCD20 bispecific T-cell engager developed by AbbVie and Genmab. It is approved by the US FDA for relapsed or refractory diffuse large B-cell lymphoma after 2+ prior lines, relapsed or refractory follicular lymphoma after 2+ prior lines (accelerated approval). The standard regimen is step-up dosing weeks 1-3 (0.16 mg, 0.8 mg, 48 mg), then 48 mg weekly through cycle 3, every 2 weeks cycles 4-9, every 4 weeks cycle 10+; subcutaneous. Tepkinly is available in the global pharmaceutical supply chain in subcutaneous injection. The drug may or may not be locally registered in Egypt, and even when registered, a Egypt family asking for Tepkinly is often asking for a precise version of it (specific indication, specific presentation, specific schedule) that the local market has not caught up to. Reserve Meds coordinates the US-side sourcing, the validated cold-chain logistics, and the documentation packet your physician needs.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Egypt patients need Tepkinly through the named-patient pathway
The Egyptian Drug Authority (EDA), established by Presidential Decree No. 777 of 2019 to carve drug regulation out of the legacy Central Administration of Pharmaceutical Affairs (CAPA), administers the personal-use importation pathway. A treating physician in Egypt licensed by the Egyptian Medical Syndicate and the Ministry of Health applies for an import permit through the EDA when the medicine is approved by the US FDA, EMA, MHRA, PMDA, or Health Canada and a clinically suitable locally registered alternative is not available.
Several patterns drive these cases: indication lag against the FDA label and EMA label; specialty biologic and oncology cases where the local route is constrained by FX availability; payer denials in the legacy HIO; and Egyptian families using cross-border supply for the precise FDA-labeled originator product. For Tepkinly specifically, the named-patient pathway exists to handle exactly the situations the local registered route cannot: a newer FDA indication that has not yet propagated to Egypt labeling, a presentation or strength the local agent does not reliably carry, a payer denial that is uneconomic to appeal, or a biomarker-defined regimen where the prescriber's clinical judgement runs ahead of the local label's molecular language. In each pattern, the named-patient pathway is the mechanism that connects a Egypt-licensed physician's clinical decision with US-sourced, FDA-labeled Tepkinly for a specific patient.
Tepkinly (FDA May 2023 for relapsed or refractory DLBCL post 2+ lines, follicular lymphoma accelerated approval June 2024) is the subcutaneous CD3xCD20 bispecific T-cell engager option in the haematologic-malignancy bispecific class. Local registration is generally limited, and centres comfortable with the step-up dosing CRS/ICANS monitoring profile drive the case mix.
The EDA named-patient pathway for Tepkinly
A complete application typically includes a clinical justification letter from the treating physician (diagnosis, severity or stage, prior therapies, biomarker results where relevant, why Tepkinly is appropriate, why the locally available alternative is not suitable for this case); the treating physician's Egypt license verification (issued by Egyptian Medical Syndicate and Ministry of Health and Population); an anonymised patient identifier where the regulator submission allows; full product details (brand name Tepkinly, generic epcoritamab, manufacturer AbbVie and Genmab, strength subcutaneous injection, quantity requested calibrated to the planned cycles or treatment duration); the destination dispensing facility name, license number, and pharmacy in charge; and a chain-of-custody plan describing how the medicine will move from the US manufacturer through the importer to the dispensing pharmacy, including cold-chain handling at 2 to 8 degrees Celsius from the US manufacturer through to the dispensing pharmacy.
For Tepkinly, the clinical justification typically rests on documentation of CD20 expression; CRS and ICANS monitoring during step-up where applicable, line of therapy and prior treatments, and a clear statement of why this medicine is the appropriate next step in this patient's care.
Approval timelines for routine cases are typically 10 to 30 business days from a complete filing. Complex cases (rare indication, paediatric application, larger multi-cycle quantities, gene therapy or cell therapy logistics, first-import scrutiny on a presentation new to the local route) can extend to 5 to 8 weeks. The EDA retains discretion on timing, and we do not promise specific durations.
Where Tepkinly gets dispensed in Egypt
A small group of Egypt institutions handle named-patient imports as established workflow, with in-house import pharmacy infrastructure and physicians experienced with the application set. Tertiary and major private hospitals that fit this profile include 57357 Children's Cancer Hospital in Cairo (paediatric oncology referral), Magdi Yacoub Foundation Aswan Heart Centre, Cleopatra Hospital Group facilities in Cairo and Alexandria, As-Salam International Hospital in Maadi, Dar Al Fouad Hospital in 6th of October City, El Gouna Hospital, Ain Shams University Hospital, Cairo University Kasr Al Ainy Hospital, Mansoura University specialty centres, Alexandria University specialty centres, and the larger private hospitals in New Cairo and 6th of October.
For physicians at smaller hospitals without internal import infrastructure, the common pattern is to route through a Cairo, Alexandria, and the new administrative capital-based specialty importer that holds a pharmaceutical establishment license and files the EDA application on the prescribing physician's behalf. The medicine then moves into the prescribing hospital's pharmacy under chain-of-custody documentation, where the patient receives the first dose under physician supervision; subsequent doses self-administered at home after injection training.
Real cost picture for Tepkinly in Egypt
US WAC for Tepkinly is approximately USD 16,800 per vial, which translates to USD 200,000 to USD 240,000 first year. The Egyptian pound floats with material volatility against the dollar; a working reference rate of approximately 48 EGP to 1 USD applies for illustrative conversion, but live quotes track current FX, so the annual reference range converts accordingly when expressed in EGP at US WAC equivalents.
International validated cold-chain logistics typically run USD 450 to USD 1,600 (varies materially with EGP volatility) per shipment depending on destination city, urgency, and pack size. Egypt customs and EDA permit fees are nominal relative to drug cost. Reserve Meds' concierge fee is itemised separately on every firm quote.
On the insurance side, each Egypt insurer assesses named-patient imports case by case. Local payer cover is administered through the new Universal Health Insurance System (UHIS, rolling out by governorate), the legacy Health Insurance Organization (HIO) for legacy enrollees, MetLife Egypt, AXA Egypt, Allianz Egypt, Misr Insurance Holding Company, and private specialty cover for high-net-worth families. We do not promise coverage from any insurer. The US manufacturer copay programmes and patient assistance programs do not extend internationally; cross-border patients pay cash or rely on local payer coverage where it applies.
Clinical evidence behind Tepkinly
Tepkinly's pivotal EPCORE NHL-1 (relapsed/refractory DLBCL, ORR approximately 63% with high complete response rates) anchored the DLBCL accelerated approval. EPCORE FL-1 supports the follicular lymphoma expansion. The subcutaneous route distinguishes operational workflow from IV bispecifics.
Typical timeline for Tepkinly in Egypt
EDA routine processing is typically 10 to 30 business days from a complete filing. For Tepkinly specifically, cold-chain shipment adds 2 to 3 days versus an ambient small molecule because validated thermal packaging, continuous temperature monitoring, and customs clearance scheduled to avoid extreme-heat exposure are non-negotiable. End-to-end, most cases complete within 3 to 6 weeks from first complete documentation to dispensing or first dose. For longer treatment courses, we coordinate cycle-by-cycle or quarterly resupply so the patient never approaches an empty pharmacy shelf.
What your physician needs to provide
For a Egypt-licensed physician prescribing Tepkinly through the EDA pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's diagnosis with relevant staging or severity language for the indication, the prior therapy history, the rationale for Tepkinly as the appropriate next step, and the precise FDA-labeled regimen (dose, route, frequency, expected duration). For Tepkinly specifically, the FDA-approved regimen is step-up dosing weeks 1-3 (0.16 mg, 0.8 mg, 48 mg), then 48 mg weekly through cycle 3, every 2 weeks cycles 4-9, every 4 weeks cycle 10+; subcutaneous.
For Tepkinly, the relevant molecular or laboratory documentation includes CD20 expression; CRS and ICANS monitoring during step-up. The letter references the test results that establish the patient's eligibility for the FDA-labeled indication. The treating physician's Egypt license number, the dispensing facility license number, and the pharmacy in charge complete the package. Monitoring requirements relevant to Tepkinly (baseline labs, imaging cadence, adverse-event surveillance) are stated in the letter and operationalised by the prescribing physician's team.
Monitoring for Tepkinly: CRS and ICANS monitoring particularly during the step-up dosing (cycle 1 with doses on days 1, 8, 15), corticosteroid premedication for cycle-1 doses, tocilizumab availability, CBC, comprehensive metabolic panel, tumour lysis syndrome monitoring with high disease burden. Adverse-event profile: Cytokine release syndrome (boxed warning), ICANS, serious and opportunistic infections, neutropenia, tumour flare, hypersensitivity. CRS prophylaxis with corticosteroids during step-up is standard.
Common questions about Tepkinly in Egypt
Will my insurer cover this? Each Egypt insurer (the new Universal Health Insurance System (UHIS, rolling out by governorate), the legacy Health Insurance Organization (HIO) for legacy enrollees, MetLife Egypt, AXA Egypt, Allianz Egypt, Misr Insurance Holding Company, and private specialty cover for high-net-worth families) assesses named-patient imports case by case. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is Tepkinly already locally registered in Egypt? Local registration status can shift over time; Tepkinly may already be on the Egypt register for some indications but not others, or the registered presentation may not match what the prescriber needs. The EDA pathway exists precisely to bridge these gaps and is the cleanest legal route when the local supply chain does not match the prescription.
What about competitors? Alternatives in the same therapeutic class include glofitamab (Columvi), mosunetuzumab (Lunsumio), CD19 CAR-T (Yescarta, Breyanzi, Kymriah), polatuzumab + rituximab + bendamustine. Choice depends on the patient's full profile, prior therapy, biomarker status, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed.
How does the cold chain work? This medicine requires cold-chain handling at 2 to 8 degrees Celsius from manufacture through to dispensing. Reserve Meds uses validated thermal packaging with continuous temperature logging. Customs clearance is scheduled to avoid prolonged tarmac exposure. The cold chain is broken only at the dispensing pharmacy.
Will my US manufacturer assistance program help? US patient assistance programs (PAP), copay cards, and bridge programs from Merck, Pfizer, AstraZeneca, Lilly, Roche, Genentech, Novartis, AbbVie, Janssen, Gilead, Biogen, BMS, and other manufacturers are generally restricted to US residents with US prescriptions filled at US pharmacies. Cross-border patients pay cash or use local payer cover.
What if treatment is multi-year? For long-running treatment, we coordinate cycle-by-cycle or quarterly resupply through the same EDA pathway, with each shipment authorised against the same physician documentation set updated for the current cycle. Patients never need to navigate the supply chain themselves.
Where is the medicine actually administered? After the first physician-supervised dose, most patients self-administer at home using the prefilled syringe or autoinjector pen after a brief injection-technique training. Home refrigeration is required; we provide a patient onboarding kit.
What if my physician is at a smaller clinic that does not import directly? The standard pattern is to route through a Cairo, Alexandria, and the new administrative capital-based specialty importer that holds a pharmaceutical establishment license. The importer files the EDA application on behalf of the prescribing physician, takes delivery of the medicine, and transfers it under chain-of-custody to the prescribing facility's pharmacy.
Operational notes for the EDA workflow
Operationally, the EDA personal-import pathway requires the treating physician's letter routed through the Egyptian Medical Syndicate and Ministry of Health channels. Submissions go through the EDA office or its appointed agent. Common reasons for delay are FX availability (the import is a USD-denominated purchase and FX clearance through the Central Bank of Egypt is typically the rate-limiting step), incomplete diagnosis-to-FDA-label fit, or chain-of-custody plans that do not specify continuous temperature logging. The new Universal Health Insurance System is rolling out by governorate and coverage assessment is uneven across the country.
Where Reserve Meds fits in Tepkinly cases
Reserve Meds is a US-based concierge coordinator. We do not replace your prescribing physician, we do not replace the EDA, and we do not replace your dispensing pharmacy. For Tepkinly specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated cold-chain logistics with appropriate temperature monitoring into Egypt, plan cycle-by-cycle resupply across longer treatment courses, and assign a single named coordinator through the case. Standard NPP coordination under our cold-chain biologic playbook applies.
Next step
If your Egypt physician has prescribed Tepkinly and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.